Analysis of Immediate Urinary Continence Predictors After RS-RARP

Analysis of Immediate Urinary Continence Predictors After Retzius-sparing Robot-assisted Radical Prostatectomy: A Single-center Retrospective Clinical Study

This study is a retrospective, single-center clinical trial. It aims to retrospectively analyze the immediate postoperative urinary continence recovery in prostate cancer patients who underwent Retzius-sparing robot-assisted radical prostatectomy in the investigators' center. Based on the general conditions of patients, relevant perioperative clinical indicators, and parameters related to the sphincter and prostate gland measured by MRI, it explores the influencing factors of immediate urinary continence recovery after Retzius-sparing robot-assisted radical prostatectomy in prostate cancer patients and constructs a relevant prediction model, thereby providing clinical guidance value for predicting immediate postoperative urinary continence recovery.

Inclusion Criteria:

• Prostate cancer diagnosed by prostate biopsy and underwent Retzius-sparing robot-assisted radical prostatectomy in the investigators' hospital.
• Received plain and contrast-enhanced pelvic or prostate MRI examinations before surgery.
• Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1.
• Complete clinicopathological data.
• In good general condition, without infections, autoimmune diseases, hematological diseases or other malignant tumors.
• Complete postoperative follow-up data, with a postoperative follow-up time of no less than 6 months.

Exclusion Criteria:

• The patient has surgical contraindications.
• The patient has contraindications for MRI examination.
• Preoperative presence of congenital urinary system malformations, urinary incontinence or severe lower urinary tract symptoms, and with a history of urinary catheter or previous transurethral resection of the prostate (TURP) surgery.
• Having received neoadjuvant treatments that may affect the results of this study, such as radiotherapy or hormonal therapy.
• The patient has other concurrent malignant tumors.
• The patient has delayed extubation (> 14 days).
• The patient's clinical, imaging and pathological data are incomplete or the patient is lost to follow-up.